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The Bayesian Model on
Human Papillomavirus
Vaccination in Italy
Lacks Transparency
To the Editor:
We refer to a recently published
article1 that shows a new Bayesian
method, applied to assess a vaccination
strategy preventing human papillomavirus
(HPV)-related diseases. The article basi-
cally describes a model for the economic
evaluation of the quadrivalent HPV vac-
cine in Italy, concluding that it is a cost-
effective strategy. Although any model,
Bayesian or Frequentist, should be
“populated” with reliable data,2 we felt
some concern about many “inputs” re-
garding the Italian setting that could
weaken the authors’ conclusions. We have
listed some of the main ones.
 Real data on Italian vaccination
coverage are referenced by an ab-
stract,3 without specifying that this
refers to a very small region in Italy
(Basilicata, 0.97% of the whole
Italian population). Thereafter, table 1
refers for vaccination compliance
and coverage to another article,
published in Italian, focussed on the
efficacy of the quadrivalent vaccine.4
 Data on health states associated with
HPV-related diseases refer to another
abstract,5 then unspecified Italian utility
weights for health states were applied,
but to our knowledge, no utility tariffs
have been validated so far in Italy.
 Utilities of cervical cancer, genital
and cervical lesions, all refer to an
article on the costs of varicella-
related hospitalizations in table 1.6
 The vaccine price is not consistent
with published data,7 and we could
not find the figure used as a mean
(h69.13, see table 1) in the refer-
ences.8,9
More in general, the authors state
that the cost-effectiveness of the quad-
rivalent vaccine is proven, ignoring the
other, bivalent vaccine against HPV. As
3 recent critical reviews10–12 on eco-
nomic evaluations regarding HPV
vaccines—not cited in the article—
concluded that long-term models on
HPV vaccination lack transparency in
key assumptions and methodological
choices, we wonder whether the results
of this model (producing a “virtual”
follow-up of 90 y) can really be con-
sidered more reliable than the others
already published.
Livio Garattini, PhD,
Katelijne van de Vooren, MSc
CESAV, Center for Health Economics
“Mario Negri” Institute for Pharmacological
Research, Ranica, Italy
The authors declare no conflict of interest.
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Transparency or Proper
Study Valuation
Procedures Missed?
To the Editor:
We wish to thank the Editor for
giving us the opportunity to think about
and resolve a few potential issues with
our paper. Garattini and colleagues have
questioned the meaningfulness of the
evidence used to inform some of the
crucial parameter used in our model. This
is because of a misalignment in the ref-
erence list, as a result of which, Table 1 in
the paper points to the wrong references.
We have fixed this and present the cor-
rected version of Table 1 below.
Incidentally, we notice that the
online appendix to the paper1 actually
has all the correct references and de-
scribes in detail all the aspects of the
modeling presented in the paper. We
find it slightly bizarre that Garattini and
colleagues have taken such a critical
stance on our work, but have failed to
cross-check the most technical aspects
with all the available material.
Garattini and colleagues also raise
a few criticisms to our general method-
ology. Firstly, they question the rele-
vance of data from the region of
Basilicata on the parameter representing
vaccination coverage. We would like to
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point out that, although not covering a
very large area, Basilicata was the only
Italian region to implement a multicohort
vaccination program, including 4 cohorts
of girls aged 12, 15, 18, and 25 years.
The empirical evidence derived by the
Basilicata vaccination register has been
published in a full paper (the GIOVE
study2). In addition, this information is
not used at face value, but the uncertainty
underlying the estimation is fully ac-
knowledged and propagated through the
entire Bayesian model. The prior dis-
tribution of parameters that play a rele-
vant role in the cost-effectiveness of
vaccination, such as coverage rates in 4
cohorts, were drawn directly from the
real-world data (information uniquely
registered in the Basilicata Region) rather
than from assumptions. The rates of
coverage are particularly important when
levels r50% are achieved in a single
cohort of girls; and in this situation, a
vaccination including a cohort of both
boys and girls can improve the cost-ef-
fectiveness as a result of the increased
clinical benefits determined by herd im-
munity. Actually, we must be wondering
whether the most economic and clinically
effective decision is provided by the
immunization of both sexes or by an in-
crease in the coverage rate in a single
cohort of females. Probably, the latter
might be more complicated and less ef-
fective than expected. Increasing the
coverage rate may require complex in-
terventions, a long period of time, and
a significant incremental cost that could
determine a diseconomy of scale. Truly,
a scarce result when compared with the
huge investment that is needed to in-
crease the baseline rate value by 1 per-
centage point. Our study reported some
indirect and preliminary indication;
however, a specific Bayesian dynamic
model addressing the cost-effectiveness
of a vaccination program that includes a
cohort of boys and girls has already been
designed and results will be assessed and
published shortly.
As for patients’ health-state pref-
erences, we agree with Garattini and
colleagues that they represent a highly
sensitive variable for the economic
evaluations. In this case, we developed
an algorithm for the fully computerized
administration of a Time Trade-Off
questionnaire; this was validated and
published in 2011.3 In that publication,
the standardized elicitation of utilities
was focused on cervical intraepithelial
neoplasia (grades 2 and 3), anogenital
warts, and cervical cancer exclusively.3
Thus, to include a broader range of human
papillomavirus (HPV)-induced patholo-
gies (which were indeed considered in
the model developed in the BEST study)
and a larger sample size, we used data
from an ongoing study that involved
>450 patients. Preliminary results from
this large study have been communicated
or presented in several congresses (in-
cluding HTAi4) and the overall evalua-
tion will be published as soon as it is
completed. We believe that it is note-
worthy that the elicitation of each utility
used to inform our model relied on a
solid and well-acknowledged proce-
dure.3,5,6 Similarly to the point we have
made earlier, by using a fully Bayesian
model, we incorporated the uncertainty
in the estimated values of utilities.
Another issue is about the vaccine
price. We modeled this parameter using
a probability distribution eliciting the
information about the mean unit price
of h69.13 and encoding the assumption
that 95% of the most plausible values
were included in the interval between
h60.16 and h79.58. This was based on
Regional tenders that occurred in 2008
and 2009 in Italy. Although in a com-
mentary published in early 2012,7 nei-
ther an accurate mean price nor a SD
were specifically reported for HPV
vaccines, a mean price per quadrivalent
vial seems to be very close to the range
of values we used to inform our model.
Although an effective public health in-
tervention is not exclusively a matter of
price,8 any value below the lower limit
of the range adopted in our study would
have had a favorable effect on the cost-
effectiveness of the vaccination strategy
that we evaluated using a Bayesian
framework.
Finally, Garattini and colleagues
wonder about the reliability of the re-
sults of our model. We are seeking to
produce a structured research program,
building on the findings of the GIOVE
study, which was related to the effective-
ness of a multicohort quadrivalent-based
vaccination program. Consequently, the
BEST study was specifically designed to
assess the cost-effectiveness of this pre-
defined vaccination strategy. Although a
potential direct comparison evaluating the
most cost-effective option between the 2
available vaccines might be interesting,
this is an objective that was not con-
sistent with the aim of the BEST study.
Although some biological char-
acteristics of HPV are uncertain, the
value of information derived from cur-
rent clinical trials is improved and the
accuracy is increased by the incorpo-
ration of prior information in a Bayesian
modeling. Further, prior distribution of
parameters significantly influencing the
impact of vaccination (ie, coverage rates
and risk factors having an effect on the
dynamic transmission of HPV infection)
were directly drawn from the health pro-
grams already implemented in Italy and
not from assumptions. Although financing
and sustaining immunization programs are
health governance challenges that public
health authorities have to deal with, an
assessment of a multicohort or both sexes
vaccination strategy with a Bayesian
model can inform decision-makers with
more reliable data about both the cost-ef-
fectiveness of interventions as well as its
budgetary implications. In conclusion,
Bayesian analytic models have a wide
range of uses and can be deemed as im-
portant and powerful tool for economic
evaluations in health care.9
Especially when associated with
the expected value of information,
Bayesian models can provide with an
accurate valuation of any future im-
plementation of a quadrivalent-based
HPV vaccination program.
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Erratum
To the Editors:
The letter by Garattini et al (The Bayesian Model on HPV Vaccination in Italy Lacks Transparency) being published in this
issue of Medical Care gave us the opportunity to reread our entire paper (Favato G, Baio G, Capone A, et al. Novel Health
Economic Evaluation of a Vaccination Strategy to Prevent HPV-related Diseases: The BEST Study. Med Care.
2012;50:1076–1085) and check every reference reported in the study. Unfortunately, we discovered that, due to our error,
some of the references listed in Table 1 were misaligned in the published paper. The corrected table can be found in this
issue in our response to the letter by Garattini et al (Transparency or Proper Study Valuation Procedures Missed?).
We regret the error and appreciate the opportunity to correct it.
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Department of Statistical Science, University College London
Gower Street
London WC1E 6BT
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